The BVA-100 (Blood Volume Analyzer) is a revolutionary instrument, developed by DAXOR Corporation and cleared by the FDA, to precisely measure blood volume in the human body.

Read More

Key Features

  • Superior  blood volume measurement
  • Results in under 1 hour
  • Clinically proven — used in leading hospitals

Latest News

Daxor Receives Two Patents, One for Measurement of Total Body Albumin and a Second Patent for Improved Accuracy of Blood Volume Measurement

Daxor has received approval from the US Patent Office for a Total Body Albumin Analyzer, US Patent # 9,002,656. The patent for the total body albumin analyzer is the first one issued for an instrument to measure the total albumin within the human body.  Albumin is the major carrier molecule in the human body for […]

Read More

Daxor Corporation Announces Hiring of Chief Financial Officer

New York, NY June 17, 2016 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces the hiring of Eric P. Coleman as its new Chief Financial Officer effective June 6, 2016, reporting directly to Michael Feldschuh, Acting President & CEO of Daxor Corporation. “Mr. Coleman will be responsible […]

Read More

Real­World Impact on Heart Failure Mortality and Readmissions of Individualized Care Guided by Blood Volume Analysis: New Data Presented at the American College of Cardiology Congress

  New York, NY April 6, 2016 ­ Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces the first interventional outcomes data to be presented in heart failure patients receiving individualized care guided by direct blood volume analysis (BVA). The data were presented at the American College of Cardiology congress by John […]

Read More